Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > ONCYs Offering to continue advancement of clinical progams

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Aug 12, 2023 9:39am

163 Views

Post# 35585171

RE:ONCYs Offering to continue advancement of clinical progams

ONCY's official statement is that the proceeds from the Offering are to be used in the continued advancement of its pelareorep clinical programs in metastatic breast and pancreatic cancers

https://www.oncolyticsbiotech.com/press-releases/detail/606/oncolytics-biotech-successfully-raises-us15-million-to

<< Previous

Bullboard Posts

Next >>

Quantum eMotion leaps by 20 per cent after Becton Dickinson deal